Published by IMARC Services Private Limited
Posted on October 6, 2021
4 min readLast updated: January 30, 2026
The global orphan drugs market is set to grow significantly from 2021 to 2026, driven by government incentives and rising demand for rare disease treatments.
According to IMARC Group’s latest report, titled “Orphan Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026“, the global orphan drugs market reached a value of US$ 174.7 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 9.8% during 2021-2026.
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviors of the consumers globally–our estimates about the latest market trends and forecast values after considering the impact of this pandemic. These observations will be integrated into the report.
Request for a free sample copy of this report: https://www.imarcgroup.com/orphan-drugs-market/requestsample
Orphan drugs refer to medications that are intended for diagnosing, preventing and treating rare, life-threatening diseases or disorders. As they traditionally had a limited market, very few pharmaceutical companies pursued research into these products. Moreover, orphan drug research is dependent on government incentives. However, the growing number of rare diseases lacking treatment, along with improving access to healthcare and spending capacity of individuals, has led to a significant rise in the demand for orphan drugs.
Market Trends and Drivers:
At present, incentives for drug development provided by government authorities in various countries are encouraging pharmaceutical companies to develop orphan drugs. For instance, the United States Food and Drug Administration (USFDA) offers benefits such as fast-track approval, protocol assistance, waiver of fees and marketing exclusivity to manufacturers, facilitating the development and commercialization of diagnostic tools and treatments devoted to rare diseases. Furthermore, there has been a rise in the development of orphan biological drugs that can prevent or treat various forms of cancer, tumors and blood disorders, which, in turn, is contributing to the orphan drugs market growth. In 2019, the Center for Drug Evaluation and Research (CDER), a division of the USFDA, approved various new orphan drug therapies for patients with numerous disorders, including tenosynovial giant cell tumor, sickle cell disease, diffuse large B-cell lymphoma, mantle cell lymphoma, acquired thrombotic thrombocytopenic purpura, beta-thalassemia, and acute hepatic porphyria.
Orphan Drugs Market 2021-2026 Competitive Analysis and Segmentation:
Competitive Landscape With Key Players:
The competitive landscape of the orphan drugs market has been studied in the report with the detailed profiles of the key players operating in the market.
Some of these key players include:
Key Market Segmentation:
The report has segmented the global orphan drugs market on the basis of drug type, disease type, phase, top selling drugs, distribution channel and region.
Breakup by Drug Type:
Breakup by Disease Type:
Breakup by Phase:
Breakup by Top Selling Drugs:
Breakup by Distribution Channel:
Breakup by Region:
Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/orphan-drugs-market
Key Highlights of the Report:
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800
The article discusses the growth and trends in the global orphan drugs market from 2021 to 2026.
Orphan drugs are medications for diagnosing, preventing, and treating rare, life-threatening diseases.
Key players include AbbVie, Johnson & Johnson, Amgen, Biogen, and Roche.
Explore more articles in the Research Reports category
